104 results about "Antibody molecule" patented technology

The invention belongs to the technical field of biology, and particularly relates to a swine monoclonal antibody of hog cholera virus Erns protein. The amino acid sequence of a heavy chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 1, the amino acid sequence of a heavy chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 2, the amino acid sequence of a light chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 3, and the amino acid sequence of the light chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 4. The full-length genes of the heavy chain and the light chain of the swine monoclonal antibody are obtained from a swine B cell specifically amplified by the same hog cholera virus Erns protein, the natural structure of an antibody molecule is reserved, affinity loss possibly caused by artificial recombination is avoided, and the swine monoclonal antibody has high affinity and specificity, and can be used for preparing the swine monoclonal antibody. And a precise molecular tool is provided for antigen structure analysis of the hog cholera virus Erns protein and establishment of a hog cholera diagnosis method. The monoclonal antibody is applied to a blocking ELISA detection method of the hog cholera virus Erns antibody, and the established Erns antibody blocking ELISA detection method is high in sensitivity and strong in specificity.

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting agent which is an anti-BCMA antibody molecule or a recombinant non-antibody protein that binds to BCMA, and a gamma secretase inhibitor.

Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Disclosed are anti-CD3 single domain antibodies and uses thereof. Also provided is a molecule, e.g., a bi-specific or multi-specific molecule, or an immunoconjugate, containing the single domain antibody. Additionally provided are nucleic acids encoding the antibody molecules, as well as vectors and host cells comprising the nucleic acids.

The present invention relates to the combined use of Fc [gamma] RIIb (CD32B) and CD20 specific antibodies, and specifically provides a method of treating a patient having a target cell expressing Fc [gamma] RIIb, the method comprising administering in combination (i) an antibody molecule that specifically binds to a surface antigen of the target cell, the antibody molecule having an Fc domain capable of binding Fc [gamma] RIIb; and (ii) an agent that inhibits or reduces binding between the Fc domain of the antibody molecule and Fc [gamma] RIIb, characterized in that the patient is selected on the basis of an increase in Fc [gamma] RIIb expression level of its target cell.

The application relates to the diagnosis and treatment of diseases, including cancer, chronic infectious diseases, autoimmune diseases, inflammatory disorders, as well as the prevention of transplant rejection. The invention provides, and involves the use of, antibody molecules that bind CD28 in a non super-agonistic manner and which also bind to CTLA-4. The antibody molecules may form part of a bispecific molecule which binds e.g. a tumor associated antigen or a further T cell antigen, such as CD3.

The present application provides chimeric anti-CD27 antibody molecules and encoding nucleic acids and expression vectors thereof. The anti-CD27 antibody molecules of the present application can specifically bind to CD27 and have effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

The invention provides a method of treating a patient having target cells that express FcγRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcγRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcγRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcγRIIb.

Humanized antibody molecules that specifically bind to CD138 are disclosed. The humanized antibody molecules can be used to treat, prevent, and / or diagnose disorders, such as multiple myeloma.

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The present invention relates to a linker unit-cytotoxic small molecule drug, an antibody specifically binding to target mucoprotein 17 (MUC17), an antibody drug conjugate and uses thereof, and a composition and a detection system containing the antibody molecule, the linker unit-cytotoxic small molecule drug and the antibody drug conjugate.

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

The present invention provides an anti-BAFFR antibody or an antigen-binding fragment thereof, a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a carrier containing the nucleic acid molecule, a host cell containing the nucleic acid molecule or the carrier, an antibody conjugate containing the antibody molecule, a chimeric antigen receptor, a pharmaceutical composition and a cassette, and their use in the preparation of a medicament for treating cancer or an autoimmune disease.

The disclosure provides compositions and methods for the preparation, manufacture and use of an adeno-associated virus (AAV) particle for the vectorized delivery of an antibody molecule that binds to tau.

The present invention relates to antibody molecules, or fragments thereof, that bind specifically to Domain 4 of ICAM-1, and to their use in the treatment of cancer in a patient. The invention also relates to polynucleotide molecules, vectors, viruses, cells, pharmaceutical compositions and kits relating to the antibody molecules, or fragments thereof.

This invention relates to the field of antibodies, and particularly to anti-EphA2 antibodies and their applications. This invention provides anti-EPH receptor A2 (EphA2) antibodies and their uses. This application also provides chimeric and humanized antibody forms of anti-EphA2 antibodies. These antibodies have high affinity for the human EphA2 protein and are promising antibody molecules for the prevention and / or treatment of EphA2-related diseases, such as EphA2-related tumors, osteoporosis, Alzheimer's disease, etc.

The invention relates to a PD1 and VEGFR2 dual binding agent. Specifically, the invention relates to an antibody molecule specifically binding to PD1 and VEGFR2, a related nucleic acid molecule, a vector and a host cell. Also provided herein are medical uses of such antibody molecules.

The invention belongs to the technical field of biological medicines, and particularly relates to an OR2H1 targeted binding protein and application thereof. The targeted binding protein has an amino acid sequence as shown in one of SEQ ID NO. 1 and SEQ ID NO. 2. The OR2H1 targeted binding protein can specifically bind OR2H1, the binding affinity reaches the nM level, the molecular weight is about 15 kDa and is far smaller than that of a traditional antibody molecule, and the OR2H1 targeted binding protein has higher tissue penetrability and lower immunogenicity. Related experiments show that the OR2H1 targeted binding protein can be used for diagnosis and treatment of OR2H1 positive tumors, targeted drug delivery and tumor immune cell treatment, and has a wide clinical application prospect.

The present application provides a chimeric anti-CD27 antibody molecule composition and its application. The anti-CD27 antibody molecule of the present application can specifically bind to CD27 and has the effects of stimulating lymphocyte proliferation, activating lymphocytes, etc.

The present application belongs to the field of biosensing technology and tumor marker instant detection, and particularly relates to a preparation method of a human epididymis protein 4 (HE4) biosensor based on electrochemical principle and detection application thereof. The present application constructs an "antibody-antigen-antibody" sandwich complex structure, realizes simple, accurate and efficient detection of serum HE4; the KB-PEI@AuNPs composite material is used as a base material, which can effectively fix antibody molecules and promote electron transmission of the electrode interface, and significantly improves the conductive performance of the sensor; by using the specific binding principle of antigen and antibody, the CoFeZn-MOF prepared by the present application has peroxidase-like activity as a nanoenzyme; when the electrode modified by the probe CoFeZn-MOF / Ab2 is detected, the nanoenzyme can catalyze H2O2 to decompose to generate active oxygen substances such as hydroxyl radicals; this redox process triggers electron transfer, thereby causing a change in the current signal, thereby exhibiting i-t rapid response characteristics, high sensitivity performance and a lower detection limit.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The present invention relates to antibody molecules and functional fragments thereof capable of binding to human glycoprotein VI (GPVI), methods for their production and therapeutic uses thereof.

Disclosed herein is a method for obtaining antibody-producing cells that express antibody molecules exhibiting high binding affinity to an antigen, comprising: contacting a population of antibody-producing cells, including cells expressing antibody molecules against an antigen on their cell surface, with a first labeled form of the antigen to enable the antigen to bind to antibody molecules on the cell surface; subsequently contacting the cells with (i) an unlabeled form of the antigen, (ii) a second labeled form of the antigen, or (iii) both the unlabeled and second labeled forms of the antigen; and collecting cells that remain bound to the first labeled form of the antigen, thereby obtaining cells that express antibody molecules with high affinity to the antigen. This method makes it possible to obtain cells expressing high-affinity antibody molecules from a pool of antibody-producing cells expressing antibody molecules with different affinities.

Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5 / 6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway, nucleic acids and vectors encoding said molecules and methods for their use.

Anti-Siglec-9 antibody molecules or binding fragments thereof are disclosed. These anti-Siglec-9 antibody molecules or binding fragments can be used to treat cancer, acute or chronic hepatitis B.

The present invention relates to a single domain antibody comprising at least one modification relative to the 4D5 antibody scaffold or human germline VH3 domain, said modification being selected from the group consisting of H35D, A78V, S93V, S93G and W103R, wherein the position numbering is according to the Kabat numbering scheme. The disulfide bond free variant further comprises at least one additional modification selected from the group consisting of C22S, A24I, A24L and C92T, with the proviso that at least one of C22S and C92T is present. The present invention also includes multi- modular antibody molecules and antibody conjugates comprising the single domain antibody, and methods of producing them. In particular, the present invention provides libraries of single domain antibodies or multi- modular antibody molecules and methods of selecting antibodies that bind to an antigen.

The invention provides a modification method of an antibody, the modification method adopts a modification molecule with a cage-shaped structure to modify the antibody, and after modification, the rigid structure of the antibody molecule is enhanced, the stability is improved, and the half-life period is prolonged. Meanwhile, by adjusting the addition amount of the modified molecules, the obtained antibody can present a nanoparticle aggregation structure, and the activity of the antibody is further improved.

The present application relates to a kind of CD47 antibodies, and the bispecific antibody comprising the CD47 antibody and VEGF antibody, the antibody molecule provided by the present application has high stability, easy to express and purify, has stronger tissue penetration, does not cause coagulation, does not bind red blood cell and cause antigen silencing effect, has excellent affinity to target point, can block relevant path, has high tumor killing efficiency, promotes tumor phagocytosis, and has multiple excellent effects such as strong, has good efficacy and safety.